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Prognosis of gastric cancer 
patients with paraaortic lymph node 
metastasis versus those with distant 
metastases
ABSTRACT
Introduction. It has long been thought that cases of advanced gastric cancer with paraaortic lymph node (PALN) 
metastasis are impossible to cure. However, several recent reports on the long-term survival of patients with PALN 
metastasis have reported an increase in the use of gastrectomy with extended lymphadenectomy, involving the 
dissection of more nodes than those invaded by the tumour, as the standard surgery for advanced gastric cancer.
Material and methods. The records of 1,015 patients with a confirmed histologic diagnosis of gastric cancer had 
been reviewed. Among patients with stage IV gastric cancer, 38 had PALN metastasis compared with 233 with 
peritoneal dissemination and 77 with hepatic metastasis.
Results. Based on tumour location, metastasis to the PALNs was more common in upper-third cancer (p < 0.01); 
hepatic metastasis was more common in well-differentiated adenocarcinoma, and peritoneal dissemination was more 
common in poorly differentiated cancer (p < 0.001). The 5-year survival in patients with metastasis to the PALNs was 
significantly higher (28.2%) than in patients with peritoneal dissemination (5.2%) or hepatic metastasis (12.0%) (p < 0.01).
Conclusions. The results reveal a better 5-year survival associated with gastric cancer patients with PALN metas-
tasis as compared with those with other distant metastases. Therefore, performing a more extended lymphadenec-
tomy in patients with gastric cancer is recommended, especially those with suspected metastasis to the PALNs.
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Introduction
The prognosis of gastric cancer patients with paraaor-
tic lymph node (PALN) metastasis is very poor, even after 
curative resection combined with systematic PALN dis-
section. PALN metastasis from gastric cancer is classified 
as distant metastasis in both the 7th classification of the 
International Union against Cancer [1] and the 3rd English 
edition of the Japanese Gastric Cancer Classification [2].
In Korea and Japan, gastrectomy with extended lym-
phadenectomy, involving the dissection of more nodes 
than those invaded by the tumour, has recently become 
the standard surgery for advanced gastric cancer. It was 
reported that there is a need for a critical application of 
PALN dissection as one modality of multidisciplinary 
treatment in patients with advanced gastric cancer in whom 
PALN metastasis is strongly suspected preoperatively [3].
This study examined the significance of PALN dis-
section in patients with advanced gastric cancer and 
evaluated the survival of patients with metastasis to the 
PALNs, compared with other distant metastases.
Material and methods
This study reviewed 1,015 gastric cancer patients, 
who underwent gastric resection at the Division of 
Gastroenterological Surgery, Department of Surgery, 
Chonnam National University Hospital, over 5 years 
(2010 to 2015). There were 38 patients with metastasis 
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to the PALNs, 77 with hepatic metastasis, and 233 with 
peritoneal dissemination. The effects of age, gender, 
tumour size, tumour location, histologic type, Borrmann 
type, and survival rate were examined. This study was 
approved by the Institutional Review Board of the Clini-
cal Research Institute of Chonnam National University 
Hospital (IRB No: CNUH-2020-379).
Operative type
The surgical procedures used for the patients with 
peritoneal dissemination included gastrectomy with 
local excision of the peritoneum, bypass only and ex-
ploration. The hepatectomy procedure consisted of 
non-anatomic limited resections: segmentectomy, left 
hemihepatectomy, and right hemihepatectomy.
Chemotherapy
Chemotherapy included a variety of drug combina-
tions. The regimens used were 5-fluorouracil, oxalipl-
atin, and leucovorin (FOLFOX), taxane and cisplatin 
(TC), and 5-fluorouracil and cisplatin.
Statistical analysis
The data were analysed statistically using the 
chi-squared test. The overall survival rates were calculat-
ed using the Kaplan-Meier method, and the differences 
between the curves were tested using the log-rank test. 
A p-value < 0.05 was considered statistically significant.
Results
Among the 1,015 patients diagnosed with gastric 
cancer who underwent surgery in the hospital within 
the study period, 38 patients (3.7%) were diagnosed 
with PALN metastasis. Table 1 describes the clinico-
pathologic features of these 38 patients (Group I), the 
233 patients with peritoneal dissemination (Group II), 
and the 77 patients with hepatic metastasis (Group III).
Table 1. Clinicopathologic features of gastric cancer patients with metastasis to paraaortic lymph node, peritoneal 
dissemination and hepatic metastasis
Variables Group I  
(n = 38) (%)
Group II 
(n = 233) (%)
Group III 
(n = 77) (%)
p value
Age (mean, year) 54.4 53.7 58.0 NS
Gender   < 0.01
Male 24 (63.2) 157 (67.4) 67 (87.0)
Female 14 (36.8) 76 (32.6) 10 (13.0)
Tumor size (mean, cm) 6.2 7.0 6.1 NS
Tumor location
Upper 21 (55.3) 17 (7.3) 8 (10.4) < 0.001
Middle 12 (31.6) 58 (24.9) 13 (16.9)
Lower 3 (7.9) 123 (52.8) 52 (67.5)
Whole 2 (5.3) 35 (15.0) 4 (5.2)
Histologic type < 0.001
Well-differentiated 4 (10.5) 15 (6.4) 17 (22.0)
Moderately differentiated 9 (23.7) 35 (15.0) 30 (38.9)
Poorly differentiated 17 (44.7) 138 (59.2) 21 (27.3)
Mucinous 3 (7.9) 13 (5.6) 5 (6.5)
Signet ring cell 5 (13.2) 14 (6.0) 0 (0.0)
    Others 0 (0.0) 17 (7.3) 4 (5.2)
Borrmann type < 0.01
     I 3 (7.9) 13 (5.6) 4 (5.2)
     II 2 (5.3) 9 (3.9) 8 (10.4)
     III 30 (78.9) 146 (62.7) 58 (75.3)
     IV 3 (7.9) 65 (27.8) 7 (9.1)
NS — not significant
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There was no significant difference in the mean age 
of the patients with PALN metastasis (54.4 years) as 
compared with patients with peritoneal dissemination 
(53.7 years) or hepatic metastasis (58.0 years). Among 
the 38 patients with PALN metastasis, 24 (63.2%) 
were male and 14 (36.8%) were female. There were 
more males than females in each group (I = 63.2%, 
II = 67.4%, III = 87.0%) (p < 0.01). There was no sig-
nificant difference in the mean tumour size (I = 6.2 cm, 
II = 7.0 cm, III = 6.1 cm). According to tumour loca-
tion, metastasis to the PALNs was more common in 
upper-third cancer (p < 0.01), peritoneal dissemination 
was more common in patients with cancer involving the 
entire stomach, and hepatic metastasis was more com-
mon in lower-third carcinoma of the stomach (p < 0.01). 
According to the histologic type, there was no significant 
difference in patients with PALN metastasis. Perito-
neal dissemination was more common in poorly dif-
ferentiated adenocarcinoma and hepatic metastasis was 
more common in well-differentiated adenocarcinoma 
(p < 0.001). Peritoneal dissemination was more com-
mon in Borrmann type IV gastric cancer (I = 7.9%, 
II = 27.8%, III = 9.1%) (p < 0.01). The 5-year survival 
rate of Group I was significantly higher (28.2%) than 





















Figure. 1. The Kaplan-Meier survival curves for patients 
with paraaortic lymph node metastasis, peritoneal 
dissemination, and hepatic metastasis. The 5-year survival 
rate for patients with metastasis to the paraaortic lymph 
node was significantly higher (28.2%) than with peritoneal 
dissemination (5.2%) and hepatic metastasis (12.0%) 
(p < 0.01)
(p < 0.01). The median progression-free survival was 
22.7 months in Group I, and 6.5 months in Group II, 
and 11.8 months in Group III.
Discussion
The prognosis of gastric cancer patients with paraaor-
tic lymph node (PALN) metastasis is very poor, even after 
curative resection combined with super-extended lymph 
node dissection. Prophylactic PALN dissection has been 
the standard of care since occult metastasis had occa-
sionally been observed in lymph nodes until a Japanese 
prospective randomized trial investigating the efficacy 
of prophylactic PALN dissection showed no survival 
advantage of PALN dissection for patients with locally 
advanced gastric cancer and no additional improvement 
in mortality and morbidity rates after PALN dissection 
[4, 5]. Since then, PALN dissection has not been routinely 
performed for patients with advanced gastric cancer. 
Thus, the significance of PALN dissection in patients with 
advanced gastric cancer was examined and the survival 
of patients with metastasis to the PALNs was evaluated, 
and compared with other distant metastases. 
The incidence of pathological metastasis to the 
PALNs has been reported to vary from 1.4% to 30% 
[5–8]. Some authors reported that micrometastases were 
detected by immunohistochemical staining in 64% of 
patients who underwent prophylactic PALN dissection 
[9]. In accordance with previous reports, the incidence 
of pathological metastasis to the PALNs made up 3.7% 
of all cases in the present study.
The appropriate treatment strategy for gastric cancer 
patients with PALN metastasis has been a controversial 
one, and the Gastric Cancer Treatment Guidelines do 
not provide any treatment recommendations regarding 
chemotherapy or surgical resection in gastric cancer pa-
tients [10]. A multi-institutional prospective randomized 
controlled trial comparing standard D2 dissection versus 
D2 plus PALN dissection for serosa-positive advanced 
gastric cancer without gross metastasis to the PALNs 
was conducted in Japan. This trial demonstrated that 
the 5-year overall survival rates did not differ between 
the two groups and concluded that prophylactic PALN 
dissection is not effective [5]. 
In contrast to their result, some investigators re-
ported that PALN dissection for advanced gastric cancer 
was effective, especially when it was done prophylacti-
cally [7] and when the number of paraaortic lymph node 
metastases were two or less [11]. It was reported that 
D2 lymph node dissection plus PAND may improve the 
overall survival for gastric cancer patients in the N3 stage 
[12]. Morita et al. also reported that rigorous and careful 
selection of patients can provide long-term survival after 
systemic lymph node dissection [8].
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Many investigators have reported that aggressive 
surgery (such as extended lymph node dissection) 
increased operative morbidity and mortality. The 
Dutch trial did not recommend a routinely extended 
lymph node dissection because of the high opera-
tive morbidity and mortality [13]. Conversely, some 
authors demonstrated that the overall postoperative 
complications and death rates did not increase after 
extended lymph node dissection and they encouraged 
performing extended lymph node dissection in patients 
with advanced gastric cancer [14, 15]. De Manzoni et 
al. reported 2.7% postoperative morbidity with PALN 
dissection in patients with advanced gastric cancer 
[16]. It was stated that the morbidity associated with 
super-extended paraaortic lymphadenectomy could 
be minimized by very careful manipulation during 
dissection of the paraaortic lymph nodes, by fine and 
thorough ligation of the retroperitoneal tissue to 
prevent lymphorrhea [17]. In the current study, the 
postoperative mortality for gastric cancer patients with 
PALN dissection was acceptable. One postoperative 
death occurred after resection. There was a 2.6% 
mortality rate, which is consistent with that reported 
previously. 
The reported postoperative 5-year survival rate of 
patients with pathologically-positive PALNs is 16–25% 
[3, 5, 6, 10, 18–20]. With several reports of long-term 
survival in cases with PALN metastasis, Korean and 
Japanese surgeons are increasingly performing exten-
sive surgery to treat advanced gastric cancers. Several 
investigators reported that gastrectomy with extended 
lymph node dissection improves the prognosis of pa-
tients with PALN metastasis, and they recommended 
removing the PALNs when the surgeon detects metas-
tasis there intraoperatively [21–23]. In the presented 
study, the 5-year survival rate was 28.2% for patients 
with PALN metastasis.
In this context, the identification of prognostic fac-
tors for patients with PALN metastasis seems important. 
However, it has not yet been well investigated. Previous 
studies have indicated prognostic factors for these pa-
tients: the macroscopic type, overall number of involved 
nodes [19], number of PALN metastases [10], age of pa-
tients and site of PALN metastasis [8]. However, most of 
these studies included few patients. In this retrospective 
study, prognostic factors were not investigated because 
of the small sample size.
In conclusion, the presented study results showed 
that gastric cancer patients with PALN metastasis 
survived longer than patients with other types of dis-
tant metastases (such as peritoneal dissemination and 
hepatic metastasis). Therefore, the authors recommend 
performing a more extended lymphadenectomy in 
patients with advanced gastric cancer, especially those 
suspected of metastasis to the PALNs.
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